Etanercept: A review of its use in the management of plaque psoriasis and psoriatic arthritis

American Journal of Clinical Dermatology

Volumn 6, Issue 2, 2005, Pages 121-136

  Goldsmith, David R ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

Etanercept; Pharmacodynamics; Pharmacokinetics; Psoriasis; Psoriatic arthritis; Therapeutic use

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CELL INFILTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; HUMAN; INJECTION SITE REACTION; KERATINOCYTE; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; TREATMENT OUTCOME;

DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17244369279     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200506020-00010     Document Type: Review

References (43)

1. Lebwohl M. Psoriasis. Lancet 2003 Apr 5; 361 (9364): 1197-204
2. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002; 62 (17): 2493-537
3. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002 Jan; 146 (1): 118-21
4. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24 (3): 518-23
5. Immunex Corporation. Enbrel® (etanercept): package insert (US) [online]. Available from URL: http://www.wyeth.com [Accessed 2004 Oct 18]
6. Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg 2003 Sep; 22 (3): 187-95
7. Gaspari A, Gottlieb AB, Kang S, et al. Enbrel improves the clinical and pathologic features of psoriasis [abstract no. 172]. J Invest Dermatol 2002 Jul; 119 (1): 236
8. Ritchlin CT, Haas-Smith SA, Shao T, et al. Etanercept lowers the frequency of circulating osteoclast precursors (OCP) and improves bone marrow edema in patients with erosive psoriatic arthritis. Arthritis Rheum 2003 Dec; 48 (12): 3660-1
9. Nestorov I, DeVries T, Zitnik R. Pharmacokinetics of etanercept, a TNF antagonist, in patients with psoriasis treated in two double-blind phase 3 trials [abstract no. P574]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 148. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
10. Nestorov I, DeVries T, Zitnik R. Comparative pharmacokinetics of etanercept in patients with psoriasis or rheumatoid arthritis [abstract no. P572]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 147. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology: 2004 Feb 6-11; Washington (DC)
11. Nestorov I, DeVries T, Zitnik R. Pharmacokinetics of etanercept in patients with psoriasis are similar after either intermittent or continuous treatment [abstract no. P575]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 148. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
12. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000 Feb; 34: 161-4
13. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 Jul 29; 356 (9227): 385-90
14. Elewski BE, Boh E, Papp K, et al. Efficacy and safety of etanercept in patients with psoriasis: results of a global phase III study [abstract no. P618]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 159. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
15. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 Dec; 139 (12): 1627-32
16. Gottlieb AB, Lowe N, Matheson R, et al. Efficacy of etanercept in patients with psoriasis [abstract no. P25 plus poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans, 12
17. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 Nov 20; 349 (21): 2014-22
18. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 Jul; 50 (7): 2264-72
19. Krueger GG, Lebwohl M, Wang A, et al. Continuance on etanercept after early incomplete response in patients with psoriasis [abstract no. P546]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 141. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
20. Gottlieb AB, Gordon K, Wang A, et al. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response [abstract no. P566]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 146. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
21. Leonardi CL, Elewski B, Camisa C, et al. The efficacy and safety of etanercept in the re-treatment of psoriasis after relapse [abstract no. P568]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 146. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
22. Krueger GG, Woolley JM, Zitnik R. The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis [abstract no. P603]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 155. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
23. Feldman SR, Kimball A, Woolley JM, et al. Clinically meaningful improvements in health-related quality of life from etanercepf therapy for patients with moderate to severe psoriasis [abstract no. P602]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 155. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
24. Wanke LA, Gottlieb AB, Lowe NJ, et al. Psoriasis patients show improved health-related quality of life when treated with etanercept (Enbrel) [abstract no. 224]. Arthritis Rheum 2002 Sep; 46 (9 Suppl.): 120
25. Lebwohl M, Gottlieb A, Mease P, et al. Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase 3 multicenter clinical trial [abstract no. P561 plus poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans, 212
26. Ory P, Sharp JT, Salonen D, et al. Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis [abstract no. OP0089]. Ann Rheum Dis 2003 Jul; 62 Suppl. 1: 92-3
27. Wanke LA, Burge D. Etanercept improves health-related quality of life in patients with psoriatic arthritis [abstract no. P531 plus poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans, 198
28. Mease PJ, Goffe BS, Metz J, et al. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [abstract no. 2019]. Arthritis Rheum 2000 Sep; 43 (9 Suppl.): 403
29. Mease PJ, Ruderman EM, Kivitz AJ, et al. Continued efficacy and safety of etanercept (Enbrel) in patients with psoriatic arthritis and psoriasis [abstract no. 343]. Arthritis Rheum 2003 Sep; 48 (9 Suppl.): 169
30. Goffe BS, Gottlieb A, Lebwohl M, et al. Etanercept in patients with psoriatic arthritis: sustained improvement in skin and joint disease [abstract no. P210]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 55. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
31. Wanke LA, Mease P, Gottlieb A, et al. Sustained improvement in activities of daily living and vitality in patients with psoriatic arthritis treated with etanercept [abstract no. P565]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 145. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
32. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38 (6): 727-35
33. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996 Dec; 39 (12): 2013-20
34. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002 Feb; 359: 579-80
35. Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004 Aug; 39: 295-9
36. Wanke LA, Malone D, Chiou C-F, et al. Cost efficacy comparison of biologics in the treatment of psoriasis [abstract no. P699]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 179. Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)
37. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003 Jun; 139: 719-27
38. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 Nov; 349 (21): 2004-13
39. Wyeth Pharmaceuticals. Enbrel®: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Nov 11]
40. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49 (5): 897-9
41. Tutrone WD, Saini R, Weinberg JM. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept. IDrugs 2004 Jan; 7 (1): 45-9
42. Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice. J Am Acad Dermatol 2003 Aug; 49 (2): 351-6
43. Sterry W, Barker J, Boehncke W-H, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 Suppl. 69: 3-17